Danaher Biotechnology: Cytiva & Downstream Bioprocessing
inpractise.com/articles/danaher-biotechnology-cytivas-downstream-portfolio
Below is an excerpt from the article. Full access is provided with an upgrade.
Cytiva, Danaher’s Biotechnology franchise, was created from the combination of two of the company’s largest historical acquisitions: GE Healthcare (2019) for $21bn, and Pall (2015) for $13.6bn. We’ve spent the last 6 months digging through old Pall and Amersham filings to understand the underlying asset quality of Cytiva’s portfolio in each product segment.
This learning journey curates the last 6 months of our work on Cytiva, Danaher’s processing business, with a focus on the downstream process and products. We explore:
-
History of how Danaher’s Biotechnology division: GE, Pall, Amersham, Pharmacia, etc
-
Upstream vs downstream bioprocess and equipment types
-
The FDA specific process and sole source products
-
Pall’s filtration portfolio; moat, competition
-
Pharmacia’s chromatography moat
-
Potential product risks to Cytiva’s portfolio
-
How Danaher may bundle Pall and Cytiva
Related Content
Danaher Cytiva: History, Moat, and Bundling Pall Filters
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Pall, Cytiva & the Bioprocessing Manufacturing Process
Former VP of Sales at Pall Corp
Danaher & the Bioprocessing FDA Approval Process
Former Head of Sales, GE Life Sciences
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities.
© 2024 IP 1 Ltd. All rights reserved.